| 货号 | HW342026 |
|---|---|
| 品牌 | abinScience |
| 种属反应性 | Human |
| 应用 | Research Grade Biosimilar |
| 宿主 | Humanized |
| 同种型 | IgG1-kappa |
| 表达系统 | Mammalian Cells |
| 克隆类型 | Monoclonal |
| 靶标 | ACT35 antigen, TXGP1L, TAX transcriptionally-activated glycoprotein 1 receptor, Tumor necrosis factor receptor superfamily member 4, TNFRSF4, OX40L receptor, CD134 |
| 内毒素水平 | Please contact the lab for this information. |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G, purified from cell culture supernatant. |
| Accession号 | P43489 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS,pH7.4. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 别名 | Vonlerolizumab,MOXR-0916,MOXR0916,RG-7888,RO7021608,CAS:1638935-72-4 |
| 背景 | Pogalizumab, also known as MOXR0916 or vonlerolizumab, is a humanized IgG monoclonal antibody that targets OX40 (CD134), a co-stimulatory receptor belonging to the tumor necrosis factor receptor superfamily (TNFRSF). OX40 is predominantly expressed on activated T cells and plays a crucial role in enhancing T-cell proliferation, survival, and cytokine production. By agonistically binding to OX40, pogalizumab aims to potentiate anti-tumor immune responses by promoting effector T-cell activity and inhibiting regulatory T-cell (Treg) functions. |
| Note | For research use only. Not for use in clinical or therapeutic applications. |
027-87433958/17302791434
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
